Holen Sie sich die Stockscreener-App
20.17
1.27%
-0.26
Handel nachbörslich:
20.13
-0.04
-0.20%
Rigel Pharmaceuticals Aktie (RIGL) Neueste Nachrichten
Eli Lilly and Rigel Pharmaceuticals: Promising Advances in Rheumatoid Arthritis Treatment - TipRanks
Will Rigel Pharmaceuticals Inc. stock benefit from AI tech trendsHigh-impact stock picks - jammulinksnews.com
Is Rigel Pharmaceuticals Inc. a good long term investmentAccelerated wealth building - PrintWeekIndia
What institutions are buying Rigel Pharmaceuticals Inc. stock nowHigh-margin investment plays - jammulinksnews.com
What analysts say about Rigel Pharmaceuticals Inc. stockStrongest growth potential - PrintWeekIndia
What drives Rigel Pharmaceuticals Inc. stock priceHigh-margin investment plays - Autocar Professional
Institutional investors have a lot riding on Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) with 65% ownership - simplywall.st
Eli Lilly and Rigel Pharmaceuticals Advance Rheumatoid Arthritis Study with LY3871801 - TipRanks
Rigel Pharmaceuticals Inc. Stock Analysis and ForecastFastest-growing stock picks - jammulinksnews.com
(RIGL) Proactive Strategies - news.stocktradersdaily.com
What makes Rigel Pharmaceuticals Inc. stock price move sharplyHigh Potential Stock Ideas - newser.com
Why Rigel Pharmaceuticals Inc. stock attracts strong analyst attentionFree Top-Rated Stock Analysis - Newser
H.C. Wainwright Reiterates a Buy Rating on Rigel Pharmaceuticals (RIGL) - Insider Monkey
(RIGL) Long Term Investment Analysis - news.stocktradersdaily.com
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | RIGL Stock News - GuruFocus
Rigel Pharmaceuticals, Inc. Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - 富途牛牛
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NA - GuruFocus
Recent 11% pullback isn't enough to hurt long-term Rigel Pharmaceuticals (NASDAQ:RIGL) shareholders, they're still up 112% over 1 year - simplywall.st
Rigel Pharmaceuticals’ SWOT analysis: promising pipeline drives stock potential By Investing.com - Investing.com Canada
Rigel Pharmaceuticals’ SWOT analysis: promising pipeline drives stock potential - Investing.com
High-grade Glioma Market Expected to Experience Major Growth by 2034, According to DelveInsight | Rigel Pharma, Orbus Therapeutics, BioMimetix, Bayer, MedImmune, DNAtrix, Chimerix, CNS Pharma - Barchart.com
Wellington Management Group LLP Makes New Investment in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Sold by Nuveen Asset Management LLC - Defense World
Two Sigma Investments LP Makes New $1.03 Million Investment in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World
Rigel Pharmaceuticals at Jefferies Conference: Strategic Growth and Innovation By Investing.com - Investing.com Nigeria
Millennium Management LLC Takes $1.19 Million Position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World
Rigel Pharmaceuticals at Jefferies Conference: Strategic Growth and Innovation - Investing.com
Rigel Pharma To Present At Jefferies Global Healthcare Conference; Webcast At 12:50 PM ET - Nasdaq
Deutsche Bank AG Increases Holdings in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Average Rating of “Hold” from Brokerages - Defense World
Is Rigel Pharmaceuticals (RIGL) Stock Undervalued Right Now? - Yahoo Finance
Rigel to Present at the Jefferies Global Healthcare Conference - StreetInsider
Director Lapointe Anthony Gregg was granted 2,500 shares, increasing direct ownership by 25% to 12,500 units (SEC Form 4) - Quantisnow
Director Hannah Alison L. was granted 2,500 shares, increasing direct ownership by 31% to 10,625 units (SEC Form 4) - Quantisnow
Wall Street Analysts See a 71.97% Upside in Rigel (RIGL): Can the Stock Really Move This High? - sharewise
0.97%
0.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):